放疗联合西妥昔单抗治疗后出现严重皮肤毒性：一例报告
Severe cutaneous toxicity following treatment with radiotherapy and cetuximab: a case report.
作者信息
Azad Arun
机构信息
Ludwig Institute for Cancer Research, University of Melbourne, Austin Hospital, Austin Health, 145-163 Studley Road, Heidelberg, Victoria, 3084, Australia.
出版信息
Cases J. 2009 Jan 7;2(1):25. doi: 10.1186/1757-1626-2-25.
Abstract
While the addition of cetuximab to radiotherapy improves clinical outcomes in locoregionally advanced head and neck squamous cell cancers, there are a small number of reports of severe radiation dermatitis occurring with this therapeutic combination. We present the case of a 69 year old male who developed severe radiation dermatitis following treatment with cetuximab and radiotherapy for a locoregionally advanced head and neck squamous cell cancer.
摘要
虽然在局部晚期头颈部鳞状细胞癌的放疗中添加西妥昔单抗可改善临床疗效，但有少数报告称这种治疗组合会引发严重的放射性皮炎。我们报告了一例69岁男性患者的病例，该患者在接受西妥昔单抗和放疗治疗局部晚期头颈部鳞状细胞癌后出现了严重的放射性皮炎。
相似文献
1
Severe cutaneous toxicity following treatment with radiotherapy and cetuximab: a case report.
Cases J. 2009 Jan 7;2(1):25. doi: 10.1186/1757-1626-2-25.
2
Management of severe bio-radiation dermatitis induced by radiotherapy and cetuximab in patients with head and neck cancer: emphasizing the role of calcium alginate dressings.
Support Care Cancer. 2019 Aug;27(8):2957-2967. doi: 10.1007/s00520-018-4606-2. Epub 2018 Dec 19.
3
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10.
4
A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.
Radiother Oncol. 2021 Apr;157:203-209. doi: 10.1016/j.radonc.2021.01.032. Epub 2021 Feb 9.
5
Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
Ann Oncol. 2011 Oct;22(10):2191-200. doi: 10.1093/annonc/mdr139. Epub 2011 May 23.
6
Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
Eur J Cancer. 2010 Jul;46(11):1979-89. doi: 10.1016/j.ejca.2010.05.015. Epub 2010 Jun 17.
7
Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
Crit Rev Oncol Hematol. 2017 Dec;120:98-110. doi: 10.1016/j.critrevonc.2017.10.011. Epub 2017 Oct 31.
8
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
N Engl J Med. 2006 Feb 9;354(6):567-78. doi: 10.1056/NEJMoa053422.
9
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):21-9. doi: 10.1016/j.ijrobp.2016.04.030. Epub 2016 May 7.
10
Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Clin Oncol (R Coll Radiol). 2016 Jan;28(1):50-61. doi: 10.1016/j.clon.2015.09.002. Epub 2015 Oct 9.
引用本文的文献
1
Development and Healing Process of Severe Radiodermatitis in Patients With Head and Neck Cancer Undergoing Radiotherapy: A Scoping Review.
Nurs Res Pract. 2024 Dec 31;2024:1940552. doi: 10.1155/nrp/1940552. eCollection 2024.
2
Cetuximab: its unique place in head and neck cancer treatment.
Biologics. 2013;7:77-90. doi: 10.2147/BTT.S43628. Epub 2013 Apr 15.
3
Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy.
Radiol Med. 2012 Feb;117(1):125-32. doi: 10.1007/s11547-011-0716-3. Epub 2011 Sep 2.
4
Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab.
Strahlenther Onkol. 2011 Jun;187(6):373-7. doi: 10.1007/s00066-011-2217-7. Epub 2011 May 16.
5
Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.
Curr Oncol. 2010 Jul;17 Suppl 1(Suppl 1):S18-30. doi: 10.3747/co.v17is1.615.
本文引用的文献
1
Severe skin reaction secondary to concomitant radiotherapy plus cetuximab.
Radiat Oncol. 2008 Jan 28;3:5. doi: 10.1186/1748-717X-3-5.
2
Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
Ann Oncol. 2008 Jan;19(1):142-9. doi: 10.1093/annonc/mdm400. Epub 2007 Sep 4.
3
Severe cutaneous reaction during radiation therapy with concurrent cetuximab.
N Engl J Med. 2007 Aug 2;357(5):514-5. doi: 10.1056/NEJMc071075.
4
Acneiform rash secondary to cetuximab plus head and neck radiotherapy.
Radiother Oncol. 2007 Oct;85(1):171. doi: 10.1016/j.radonc.2007.04.034. Epub 2007 May 24.
5
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
N Engl J Med. 2006 Feb 9;354(6):567-78. doi: 10.1056/NEJMoa053422.
6
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
Br J Dermatol. 2004 Jul;151(1):238-41. doi: 10.1111/j.1365-2133.2004.06026.x.
7
Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.
Br J Dermatol. 2001 Jun;144(6):1169-76. doi: 10.1046/j.1365-2133.2001.04226.x.
Zotero 插件